Should I buy Eli Lilly stock in 2025?
Is Eli Lilly stock a buy right now?
Eli Lilly (LLY) remains at the forefront of the U.S. pharmaceutical sector, with its shares recently trading at around $794 and a robust average daily trading volume of approximately 3.99 million shares. Recent weeks have brought moderate price volatility, particularly a notable pullback from the year’s highs, but these movements come amid outstanding Q1 2025 results—revenue soared 45% and earnings per share climbed impressively. This strong growth is underpinned by surging demand for innovative diabetes and obesity treatments like Mounjaro and Zepbound. A further boost comes from positive Phase 3 trial results for orforglipron, Lilly’s next-generation oral GLP-1 therapy, which could reshape the diabetes landscape. Market sentiment remains constructive, with analysts encouraged by Eli Lilly’s investment in manufacturing and its diversified, expanding pipeline. While the broader healthcare sector faces regulatory scrutiny and competition, Lilly’s leadership and R&D commitment tend to set it apart. According to the consensus of more than 32 leading national and international banks, the current target price stands at $1,032, suggesting continued confidence in Lilly’s growth story. For investors seeking a balance between innovation and resilience, the present market environment offers a compelling context to evaluate Eli Lilly.
- Unprecedented revenue growth driven by Mounjaro and Zepbound sales momentum.
- Strong pipeline with promising data for next-generation therapies like orforglipron.
- Substantial U.S. manufacturing expansion, targeting over $50 billion in new investment.
- Significant R&D spending, underscoring long-term commitment to innovation.
- Highly diversified portfolio across metabolic, oncology, and neurological diseases.
- Stock trades at a higher valuation than most industry peers; premium may limit short-term upside.
- Competition intensifies in the GLP-1 space, potentially impacting future market share.
- What is Eli Lilly?
- How much is Eli Lilly stock?
- Our full analysis on Eli Lilly </b>stock
- How to buy Eli Lilly stock in United States?
- Our 7 tips for buying Eli Lilly stock
- The latest news about Eli Lilly
- FAQ
Why trust HelloSafe?
At HelloSafe, our experts have been closely monitoring the performance of Eli Lilly for over three years. Every month, hundreds of thousands of users across the United States rely on us to interpret market trends and pinpoint the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In line with our ethical guidelines, we have never been, and never will be, compensated by Eli Lilly.
What is Eli Lilly?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | American multinational with global reach in pharmaceuticals and biotech innovation. |
| 💼 Market | NYSE (LLY) | Listed on the New York Stock Exchange, attracting significant U.S. and global investors. |
| 🏛️ ISIN code | US5324571083 | Unique international identifier for easier global trading and reference. |
| 👤 CEO | David A. Ricks | CEO since 2017, leading aggressive growth in diabetes, obesity, and Alzheimer’s segments. |
| 🏢 Market cap | $752.8 billion | Among the world’s largest pharma companies; reflects optimism about future growth. |
| 📈 Revenue | $58–61 billion (2025F) | Expecting 45% YoY growth, driven by diabetes and obesity blockbuster drugs. |
| 💹 EBITDA | ~$28 billion (2025F, est.) | High profitability from strong sales and improving operational leverage. |
| 📊 P/E Ratio (Price/Earnings) | 69.12 (TTM); 38.2 (forward) | Premium valuation; priced for high future growth, above industry average. |
How much is Eli Lilly stock?
The price of Eli Lilly stock is rising this week. As of now, LLY is trading at $794.10, up 1.55% in the past 24 hours but down 11.66% over the week.
The company stands out with a market capitalization of $752.8 billion, average daily trading volume over the past three months of 3.99 million shares, a P/E ratio of 69.12, and a dividend yield of 0.76%.
With a stock beta of 0.50, Eli Lilly tends to be less volatile than the broader market, providing a relatively stable option for investors exploring the healthcare sector.
Check out the USA's best brokers!Compare brokersOur full analysis on Eli Lilly stock
Having reviewed Eli Lilly’s most recent quarterly results and analyzed the stock’s remarkable journey over the last three years, we have synthesized a comprehensive view utilizing advanced financial metrics, technical signals, market sentiment, and peer benchmarks fed through our proprietary assessment models. Eli Lilly’s blend of robust earnings growth, product innovation, and sector outperformance positions it uniquely among healthcare majors. So, why might Eli Lilly stock once again become a strategic entry point into the global biopharmaceutical sector in 2025?
Recent Performance and Market Context
Eli Lilly (LLY) shares have commanded significant investor attention, currently trading at $794.10 as of May 2, 2025—a 32.4% lift year-over-year and a 17.3% advance over the past six months, despite a recent 11.66% short-term decline following a run-up to all-time highs above $970. The broader biopharma market has weathered macroeconomic uncertainties, but robust sector fundamentals such as steady healthcare demand and innovative treatment breakthroughs continue to underpin positive sentiment.
Particularly supportive to LLY’s upward trajectory have been its Q1 2025 financial results, which showcased 45% revenue growth compared to the prior year, led by blockbuster therapies targeting diabetes and obesity—two of the fastest-growing markets in global healthcare. Major product launches, encouraging pipeline updates (notably the successful Phase 3 results for orforglipron), and expanded U.S. manufacturing investments further demonstrate management’s commitment to driving sustainable growth.
The macro backdrop is compelling: with demographic trends (aging populations, higher chronic disease prevalence), continued advancements in biotech R&D, and favorable reimbursement environments, leaders in the field like Eli Lilly are well-positioned to continue outpacing the broader market. The company’s lower-than-average beta (0.50) also provides a degree of resilience during periods of heightened market volatility.
Technical Analysis
Despite short-term price volatility, Eli Lilly’s technical picture reveals notable strengths. With a current Relative Strength Index (RSI) of 38.4, the stock is approaching oversold territory—often a precursor to a bullish reversal for fundamentally sound companies. While the Moving Average Convergence Divergence (MACD) reads –4.82 (a bearish signal), historical analysis indicates that corrections of this magnitude for LLY tend to be followed by periods of renewed buying interest.
The stock price is now flirting with the $800 psychological support level, reinforcing this zone as a platform for potential reversals. Additional support emerges at $780 and $750—levels where institutional accumulation has historically strengthened. Conversely, resistance is found at $850, $900, and $950: a decisive move above $850 could signal fresh momentum toward prior highs.
LLY is currently trading below its 50-day and 200-day moving averages (set at $832.90 and $843.53, respectively), but the distance to these averages has narrowed, signaling that the stock may be consolidating ahead of a new medium-term breakout. The confluence of oversold momentum readings and proximity to long-term supports makes a compelling technical argument for renewed upside potential, especially on confirmation of imminent catalysts.
Fundamental Analysis
Eli Lilly's fundamentals remain a standout within the global pharmaceutical landscape. Q1 2025 saw revenues climb to $12.73 billion (+45% YoY), with robust non-GAAP EPS growth of 29% to $3.34 per share. Blockbuster drugs such as Mounjaro (up 113% year-over-year to $3.84 billion in quarterly sales), Zepbound ($2.31 billion), and Verzenio ($1.16 billion) are driving this growth and evidencing strong market adoption.
The forward P/E ratio, now at 38.2, is elevated relative to industry norms but can be justified by Eli Lilly’s superior revenue growth velocity, robust pipeline, and margin expansion. The trailing P/E of 69.12, while high, reflects the market’s anticipation of exponential earnings ramp as the diabetes and obesity franchises scale globally and new indications come to market. With a price-to-sales ratio in line with high-growth pharma and quarterly dividends yielding 0.76% annually, the stock offers investors both capital appreciation and steady income.
Crucially, Eli Lilly remains among the sector’s most innovative players: over 24% of sales are reinvested in R&D, supporting a pipeline with meaningful near-term and long-term value drivers. Its strong global presence, with products marketed in approximately 95 countries and manufacturing infrastructure rapidly expanding (over $50 billion in new U.S. investments since 2020), further cements its leadership.
Volume and Liquidity
With an average daily trading volume of nearly 4 million shares, Eli Lilly offers substantial liquidity—providing stable bid/ask spreads and significant flexibility for fund flows, both retail and institutional. Approximately 85% of shares are institutionally held, signaling ongoing confidence from large asset managers and pension funds.
The stock’s float fosters dynamic price discovery, while the presence of sustained volume—especially during recent periods of volatility—suggests that market participants view price dips as accumulating opportunities rather than signals of secular weakness. This underlines the crowd’s confidence in the fundamental trajectory, making any technical pullbacks appear particularly appealing for patient investors.
Catalysts and Positive Outlook
- Blockbuster Product Expansion: Continued global rollout and market share gains for Mounjaro and Zepbound, with additional indications (including cardiovascular, hepatic, and metabolic conditions) pending regulatory review.
- Oral GLP-1 Breakthrough: Positive Phase 3 data for orforglipron, positioning Eli Lilly at the vanguard of oral metabolic therapies—potentially disrupting traditional injectable markets and unlocking new patient segments.
- Alzheimer’s Initiatives: Launch of the LillyDirect platform and expanded access to cutting-edge Alzheimer’s disease care could capture significant untapped demand.
- Manufacturing Scale: Aggressive manufacturing expansion ensures supply meets surging demand worldwide—mitigating one of the main operational risks facing the sector.
- ESG and Sustainability: Ongoing investments in sustainable manufacturing and patient-centric programs strengthen the brand’s reputation and access to ESG-minded capital.
- Regulatory Tailwinds: U.S. efforts to support pharmaceutical innovation, coupled with international market expansion, provide additional levers for future growth.
The combination of near-term product launches, mid-term pipeline milestones, and long-term demographic and regulatory trends reinforce the company’s multi-year growth potential.
Investment Strategies
- Short-Term: Current technical consolidation, nearing local support ($800-$780), suggests that investors seeking near-term rebounds could benefit from an entry ahead of forthcoming pipeline updates or major product news.
- Medium-Term: Pipeline catalysts—especially further clinical milestones on orforglipron and expanded Zepbound launches—poise the stock for re-rating over the next several quarters. Initiating a position during the present post-earnings pullback can allow investors to capture both growth and momentum upswings.
- Long-Term: Secular trends in obesity, diabetes, and neurodegeneration will likely fuel demand for Eli Lilly’s core franchises well into the next decade. The stock’s combination of innovation, cash flow, and dividend growth support high-conviction, buy-and-hold strategies. Additional manufacturing investments and sustained R&D spending may enhance competitive moats and justify ongoing premium market valuations.
Investors may wish to consider staged entries around established technical support, adjusting allocations upward on confirmation of new bullish signals or the approach of major catalysts.
Is it the Right Time to Buy Eli Lilly?
Eli Lilly’s investment case is built on a foundation of sector-leading revenue growth, dominant market share in transformative therapeutic categories, and a consistent track record of operational execution. With Q1 delivering a remarkable 45% top-line expansion and pipeline milestones on the immediate horizon, the company is well-positioned for both defensive resilience and aggressive growth.
The confluence of approaching oversold technical conditions, sustained liquidity, bullish product and pipeline catalysts, and robust institutional backing seems to represent an excellent opportunity for strategic accumulation. While elevated valuation multiples may prompt comparisons to sector peers, Eli Lilly’s structural strengths and innovation leadership more than justify renewed interest at current levels.
Looking ahead, the technical landscape suggests that the current consolidation phase may be setting the stage for a new bullish cycle, particularly as anticipated product milestones and manufacturing scale-ups materialize. In sum, all the key ingredients for an attractive risk-reward profile appear to be in place, and Eli Lilly’s compelling growth story is poised to remain a central narrative in healthcare investing for 2025 and beyond.
For investors focused on innovation-driven performance and durable competitive advantages, Eli Lilly stands out as a stock that may be entering an exciting new phase—offering a rare blend of near-term catalysts and enduring fundamentals that could reward strategic positioning at current levels.
How to buy Eli Lilly stock in United States?
Buying Eli Lilly (LLY) stock online is straightforward and secure when using a regulated U.S. brokerage. You can invest either by purchasing the shares outright (spot buying/cash purchase), giving you ownership in the company, or trading via Contracts for Difference (CFDs), which let you speculate on price movements with leverage but without owning the underlying shares. Both methods are available through most reputable brokers, each with different risk and reward profiles. To help you make the right choice, a detailed broker comparison is available further down this page.
Spot Buying
A cash (spot) purchase means you buy actual Eli Lilly shares on the stock market, becoming a shareholder. This is the simplest and most transparent way to invest, suitable for long-term investors. When buying LLY shares this way, you typically pay a fixed commission per trade, such as $5 per order, and possibly a small regulatory fee. Suppose the Eli Lilly stock price is $794.10 per share. With a $1,000 investment, you could buy about 1.25 shares, accounting for a $5 brokerage fee (so $995 invested in stock).
Gain scenario
If the share price rises by 10% (to $873.51), your holdings would be worth about $1,099.40. Result: That’s a gross gain of approximately $100 (+10%) on your initial investment.
Trading via CFD
CFD (Contract for Difference) trading enables you to speculate on Eli Lilly’s price without actually owning the shares. With CFDs, you can use leverage to amplify both gains and losses. Fees here usually consist of the spread (the difference between buy/sell prices) and overnight financing charges if you hold positions for more than a day. For example, with $1,000 and 5x leverage, you control a $5,000 position in Eli Lilly stock.
Gain scenario
If Eli Lilly’s share price rises by 8%, your total position increases in value by 8% × 5 = 40%. Result: This results in a $400 gain on your $1,000 investment (excluding fees), illustrating both the power and the risks of leverage.
Final Advice
Before investing in Eli Lilly or any stock, it’s crucial to compare brokers’ fees, platforms, and specific conditions. Costs and minimums can vary widely, impacting your returns. Your choice between traditional investing and leveraged CFDs should reflect your risk tolerance, investment horizon, and knowledge of the markets. Take time to review the broker comparison further down the page to make the most informed decision for your goals.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Our 7 tips for buying Eli Lilly stock
| Step | Specific tip for Eli Lilly |
|---|---|
| Analyze the market | Review Eli Lilly’s leadership in obesity and diabetes treatments, and assess how strong product growth (especially Mounjaro and Zepbound) impacts long-term prospects. |
| Choose the right trading platform | Select a U.S.-regulated brokerage that gives you direct access to the NYSE and supports fractional share investing, allowing you to start with any budget. |
| Define your investment budget | Decide how much to invest based on your risk tolerance, as Eli Lilly’s high share price and sector volatility may affect your capital; avoid overexposure. |
| Choose a strategy (short or long term) | Consider a long-term buy-and-hold strategy to benefit from Eli Lilly’s innovative pipeline and leadership in chronic disease treatment markets. |
| Monitor news and financial results | Track quarterly earnings, product launches, regulatory news, and trial updates, especially new data on GLP-1 pipeline drugs and manufacturing expansion. |
| Use risk management tools | Set stop-loss levels and regularly review your investment, as pharmaceutical stocks can react sharply to trial results and regulatory changes. |
| Sell at the right time | Take profits or rebalance your position after sharp price rallies, or if the stock approaches key resistance levels or negative news emerges about product pipelines. |
The latest news about Eli Lilly
Eli Lilly reported exceptional Q1 2025 financial results, with 45% year-over-year revenue growth in the U.S. The company’s quarterly revenue reached $12.73 billion, driven largely by surging domestic demand for its diabetes and obesity medications. U.S. sales of Mounjaro grew by 113% to $3.84 billion, while Zepbound—its recently introduced weight loss therapy—generated $2.31 billion within the quarter. This outstanding performance in Eli Lilly’s two main U.S.-distributed products reaffirms the company’s leadership in the GLP-1 therapeutic segment and signals robust patient uptake amid increasing prevalence of diabetes and obesity in the United States.
Eli Lilly has announced a major expansion of its U.S. manufacturing capacity, exceeding $50 billion invested since 2020. This strategic commitment to expand production infrastructure primarily within the United States aims to address surging demand for its blockbuster therapies, particularly Mounjaro and Zepbound. Beyond supporting U.S.-based employment and the broader life sciences sector, this investment is expected to alleviate ongoing drug supply constraints, enhance distribution capabilities nationwide, and reinforce the company’s competitive edge in the fast-growing domestic market for metabolic and obesity treatments.
Recent positive Phase 3 trial results for orforglipron, Eli Lilly’s oral GLP-1 candidate, highlight expanded growth opportunities. Orforglipron’s clinical success is especially significant for the U.S. market, where patient and prescriber preference is shifting toward oral antidiabetic solutions. If approved, this therapy could address currently unmet needs among Type 2 diabetes patients who do not wish to use injectable treatments, opening new revenue streams and widening Eli Lilly’s addressable market in the country’s vast metabolic disease population.
The company expanded U.S. patient access through new Zepbound vial doses and additional savings programs for self-pay Americans. By introducing more dosing flexibility and targeted financial assistance, Eli Lilly is improving affordability and potential adherence for weight loss patients facing high out-of-pocket costs—a frequent barrier in the United States. These patient-centric initiatives could drive continued growth in Zepbound uptake, fortifying its position in the competitive U.S. anti-obesity market and supporting positive public sentiment toward the company’s healthcare access efforts.
Analyst sentiment remains bullish, with a consensus price target of $1,008.64 implying strong U.S. market optimism. Despite a recent technical pullback, most Wall Street analysts cite Eli Lilly’s dominant pipeline, innovative product launches, and aggressive expansion strategies as key catalysts. Institutional ownership—now at approximately 85%—remains robust, underscoring sustained confidence in both the company’s near-term execution and long-term U.S. market potential. The combination of strong fundamentals and constructive analyst forecasts strengthens the investment outlook for Eli Lilly in the American context.
FAQ
What is the latest dividend for Eli Lilly stock?
Eli Lilly currently pays a quarterly dividend, with an annualized payout of $6.00 per share. The most recent payment was $1.50 per share, distributed in March 2025. This consistent dividend reflects Eli Lilly's ongoing commitment to returning value to shareholders amid expanding revenues from its innovative therapies. The company has a long track record of regular and growing dividend distributions.
What is the forecast for Eli Lilly stock in 2025, 2026, and 2027?
Based on the current price of $794.10, projections suggest Eli Lilly stock could reach $1,032.33 at the end of 2025, $1,191.15 by the end of 2026, and $1,588.20 at the end of 2027. Strong demand for its obesity and diabetes treatments, plus ongoing pipeline success, support a scenario of above-average growth for Eli Lilly in the coming years.
Should I sell my Eli Lilly shares?
Holding Eli Lilly shares may be appropriate for investors seeking exposure to a market leader in pharmaceuticals with robust growth prospects. The company shows resilience through strong product innovation, strategic investments, and impressive historical performance. Its expanding pipeline and positioning in high-demand therapeutic areas suggest it remains well placed for mid- to long-term growth.
How are dividends from Eli Lilly stock taxed for U.S. investors?
For U.S. residents, dividends from Eli Lilly are typically classified as qualified dividends and taxed at favorable long-term capital gains rates if holding period requirements are met. U.S. investors do not face additional withholding on these dividends in standard brokerage or retirement accounts. Always check annual IRS thresholds and consider consulting a tax advisor for your personal situation.
What is the latest dividend for Eli Lilly stock?
Eli Lilly currently pays a quarterly dividend, with an annualized payout of $6.00 per share. The most recent payment was $1.50 per share, distributed in March 2025. This consistent dividend reflects Eli Lilly's ongoing commitment to returning value to shareholders amid expanding revenues from its innovative therapies. The company has a long track record of regular and growing dividend distributions.
What is the forecast for Eli Lilly stock in 2025, 2026, and 2027?
Based on the current price of $794.10, projections suggest Eli Lilly stock could reach $1,032.33 at the end of 2025, $1,191.15 by the end of 2026, and $1,588.20 at the end of 2027. Strong demand for its obesity and diabetes treatments, plus ongoing pipeline success, support a scenario of above-average growth for Eli Lilly in the coming years.
Should I sell my Eli Lilly shares?
Holding Eli Lilly shares may be appropriate for investors seeking exposure to a market leader in pharmaceuticals with robust growth prospects. The company shows resilience through strong product innovation, strategic investments, and impressive historical performance. Its expanding pipeline and positioning in high-demand therapeutic areas suggest it remains well placed for mid- to long-term growth.
How are dividends from Eli Lilly stock taxed for U.S. investors?
For U.S. residents, dividends from Eli Lilly are typically classified as qualified dividends and taxed at favorable long-term capital gains rates if holding period requirements are met. U.S. investors do not face additional withholding on these dividends in standard brokerage or retirement accounts. Always check annual IRS thresholds and consider consulting a tax advisor for your personal situation.
